Manufacturers: AbbVie
Decnupaz (pivekimab sunirine), also known as DGN549-C or IMGN-632, is an antibody-drug conjugate (ADC) developed by AbbVie. It received FDA approval for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking AbbVie's first ADC approved for a blood cancer indication.
Decnupaz (pivekimab sunirine), also known as DGN549-C or IMGN-632, is an antibody-drug conjugate (ADC) developed by AbbVie. It received FDA approval for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking AbbVie's first ADC approved for a blood cancer indication.
Decnupaz (pivekimab sunirine) is indicated for the treatment of adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer. It is the first antibody-drug conjugate (ADC) approved for a blood cancer indication.
1 associated conditions
